- Read more »
A new Northwestern University study of 800,000 men found a dramatic increase in advanced cancer cases — a 72 percent jump in the last decade. The study suggests PSA testing
- Read more »
As a leader in urology throughout Lansing and the surrounding areas, Capital Urological Associates specializes in your urological needs. Dr. Stockall has been practicing for more than 20 years and
- Read more »
It’s a problem many women have, but few are willing to speak about. Regardless of age, 30 percent of women suffer from urinary incontinence.
A Division of Compass Health
Welcome to a new direction in health care.
Physician leaders in the Lansing area have come together to form Compass Health—a multi-specialty medical group committed to preserving the physician/patient relationship in today’s health care landscape.
At Compass Health, providing the care you need is the focus of everything we do.
The physicians and staff of Compass Health provide leading-edge patient-centered care across a range of medical specialties.
Targeted MRI/Ultrasound Fusion biopsy is the latest technology available for the detection and management of prostate cancer and Capital Urological Associates is proud to offer this new standard of care.
Historically, finding the exact location of cancer in a prostate gland has been a challenge. Conventional TRUS prostate biopsy techniques are referred to as “blind” biopsies since
physicians typically cannot easily view the specific location of any abnormal tissue. Now, using the revolutionary Artemis 3D imaging and navigation system, physicians are able to better identify and more accurately biopsy suspicious prostate cancer areas.
The MRI/Ultrasound Fusion (or MR/US Fusion) targeted biopsy procedure starts by using pre-exam MRI prostate images. These images are then fused with real-time ultrasound images to create a detailed 3D high-definition map of the prostate. This allows the physician to accurately target any visible lesions during the biopsy.
“Insert testimonial of your choice from your facility,” explains urologist Dr. Eric Stockall of Capital Urological Associates. Patients recommended for this procedure are men who, typically, have elevated and/or rising prostate-specific antigen (PSA) levels or those with a clinical concern for prostate cancer.
According to the American Cancer Society, prostate cancer is the second most common cancer in men after skin cancer, and one in seven men will be diagnosed in his lifetime. Prostate cancer can be a serious disease, but with early detection, most men have a 5 year survival rate of 90%.
Capital Urological Associates introduction of the MRI/Ultrasound Fusion Prostate biopsy system is the latest breakthrough option in providing patients with improved diagnosis and accuracy in the detection and treatment of prostate cancer.
Compass Health is a Proud Supporter of the ZERO Prostate Cancer Run/Walk
From our ZERO Cancer Run/Walk Site, you can register or join a team. We are also looking for Sponsors for this event. If you would like to sponsor this event, you can do so by clicking on the “Sponsor this Event” button from our link above.